The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Unified Huntington's disease rating scale: Reliability and consistency
Abstract
The Unified Huntington's disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity. We assessed the internal consistency and the intercorrelations for the four domains and examined changes in ratings over time. We also performed an interrater reliability study of the motor assessment. We found there was a high degree of internal consistency within each of the domains of the UHDRS and that there were significant intercorrelations between the domains of the UHDRS, with the exception of the total behavioral score. There was an excellent degree of interrater reliability for the motor scores. Our limited longitudinal database indicates that the UHDRS may be useful for tracking changes in the clinical features of HD over time. The UHDRS assesses relevant clinical features of HD and appears to be appropriate for repeated administration during clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of interference in serial verbal reactions
Stroop, J. R. (1935) · Journal of Experimental Psychology · doi:10.1037/h0054651 · Cited by 18,622
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Cited by
Scale for the assessment and rating of ataxia: Development of a new clinical scale
Schmitz-Hübsch, T., du Montcel, S. T., Baliko, L., Berciano, J., Boesch, S., Depondt, C., Giunti, P., Globas, C., Infante, J., Kang, J. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000219042.60538.92 · Cited by 1,967
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Regional and progressive thinning of the cortical ribbon in Huntington’s disease
Rosas, H. D., Liu, A. K., Hersch, S., Glessner, M., Ferrante, R. J., Salat, D. H., van der Kouwe, A., Jenkins, B. G., Dale, A. M., & Fischl, B. (2002) · Neurology · doi:10.1212/wnl.58.5.695 · Cited by 1,044
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases
Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M. B., Neil, D., Saffari, A., Mead, R., Hautbergue, G. M., Holbrook, J. D., & Ferraiuolo, L. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0377-8 · Cited by 595
Neuropsychiatric aspects of Huntington’s disease.
Paulsen, J. S. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.310 · Cited by 486
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., Greve, D., Hevelone, N., & Hersch, S. M. (2008) · Brain · doi:10.1093/brain/awn025 · Cited by 460
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Cognitive Impairment in Huntington Disease: Diagnosis and Treatment
Paulsen, J. S. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0215-x · Cited by 364
Rate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Mannini, A., Trojaniello, D., Cereatti, A., & Sabatini, A. (2016) · Sensors · doi:10.3390/s16010134 · Cited by 242
Wasser, C. I., Mercieca, E.-C., Kong, G., Hannan, A. J., McKeown, S. J., Glikmann-Johnston, Y., & Stout, J. C. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa110 · Cited by 198
Boll, M.-C., Alcaraz-Zubeldia, M., Montes, S., & Rios, C. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9610-3 · Cited by 173
Huntington's disease progression
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H. A., Sahakian, B., Hodges, J. R., Rosser, A. E., Wood, N. W., & Brooks, D. J. (1999) · Brain · doi:10.1093/brain/122.12.2353 · Cited by 169
Biological and clinical manifestations of juvenile Huntington’s disease: A retrospective analysis
Fusilli, C., Migliore, S., Mazza, T., Consoli, F., De Luca, A., Barbagallo, G., Ciammola, A., Gatto, E. M., Cesarini, M., Etcheverry, J. L., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30294-1 · Cited by 148
Huntington’s disease: Clinical presentation and treatment
Novak, M. J. U., & Tabrizi, S. J. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-381328-2.00013-4 · Cited by 137
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Busse, M., Quinn, L., Debono, K., Jones, K., Collett, J., Playle, R., Kelly, M., Simpson, S., Backx, K., Wasley, D., et al. (2013) · Journal of Neurologic Physical Therapy · doi:10.1097/npt.0000000000000016 · Cited by 97
Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease
Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H., & Wild, E. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163479 · Cited by 79
Neuroinflammation in Huntington’s Disease: New Insights with 11 C-PBR28 PET/MRI
Lois, C., González, I., Izquierdo-García, D., Zürcher, N. R., Wilkens, P., Loggia, M. L., Hooker, J. M., & Rosas, H. D. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00072 · Cited by 84
Anxiety in Huntington’s Disease
Dale, M., & van Duijn, E. (2015) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.14100265 · Cited by 83
Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01919-8 · Cited by 67
Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
Niemelä, V., Landtblom, A.-M., Blennow, K., & Sundblom, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172762 · Cited by 63
Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology
Rocha, N. P., Charron, O., Latham, L. B., Colpo, G. D., Zanotti-Fregonara, P., Yu, M., Freeman, L., Furr Stimming, E., & Teixeira, A. L. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000984 · Cited by 52
Exercise effects in Huntington disease
Frese, S., Petersen, J. A., Ligon-Auer, M., Mueller, S. M., Mihaylova, V., Gehrig, S. M., Kana, V., Rushing, E. J., Unterburger, E., Kägi, G., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8310-1 · Cited by 46
Epidemiology of Huntington disease: first post‐HTT gene analysis of prevalence in Italy
Squitieri, F., Griguoli, A., Capelli, G., Porcellini, A., & D'Alessio, B. (2016) · Clinical Genetics · doi:10.1111/cge.12574 · Cited by 43
Exercise in Huntington’s Disease: Current State and Clinical Significance
Mueller, S. M., Petersen, J. A., & Jung, H. H. (2019) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.515 · Cited by 40
Accelerated expansion of pathogenic mitochondrial DNA heteroplasmies in Huntington's disease
Wang, Y., Guo, X., Ye, K., Orth, M., & Gu, Z. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014610118 · Cited by 36
Embodied emotion impairment in Huntington’s disease
Trinkler, I., Devignevielle, S., Achaibou, A., Ligneul, R. V., Brugières, P., Cleret de Langavant, L., De Gelder, B., Scahill, R., Schwartz, S., & Bachoud-Lévi, A.-C. (2017) · Cortex · doi:10.1016/j.cortex.2017.02.019 · Cited by 33
Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington’s disease patients
Pierzynowska, K., Gaffke, L., Cyske, Z., & Węgrzyn, G. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00405-4 · Cited by 32
Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial
McGarry, A., McDermott, M. P., Kieburtz, K., Fung, W. L. A., McCusker, E., Peng, J., de Blieck, E. A., Cudkowicz, M., & for the Huntington Study Group 2CARE Investigators and Coordinators (2019) · Neurology · doi:10.1212/wnl.0000000000007244 · Cited by 24
Huntington's Disease: Prevalence and Psychological Indicators of Pain
Underwood, M., Bonas, S., Dale, M., & REGISTRY Investigators of the European Huntington's Disease Network (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12376 · Cited by 24
Age of onset and behavioral manifestations in Huntington's disease: An Enroll‐HD cohort analysis
Ranganathan, M., Kostyk, S. K., Allain, D. C., Race, J. A., & Daley, A. M. (2021) · Clinical Genetics · doi:10.1111/cge.13857 · Cited by 20
Ciriegio, A. E., Watson, K. H., Pfalzer, A. C., Hale, L., Huitz, E., Moroz, S., Roth, M. C., Snow, A. L. B., Jones, M. T., Guthrie, C. S., et al. (2022) · Neuropsychology · doi:10.1037/neu0000793 · Cited by 14
Predictors of Workplace Disability in a Premanifest Huntington’s Disease Cohort
Goh, A. M. Y., You, E., Perin, S., Clay, F. J., Loi, S., Ellis, K., Chong, T., Ames, D., & Lautenschlager, N. (2018) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.17040086 · Cited by 8
Fisher, E. R., Rocha, N. P., Morales-Scheihing, D. A., Venna, V. R., Furr-Stimming, E. E., Teixeira, A. L., & Rossetti, M. A. (2021) · Journal of Huntington's disease · doi:10.3233/jhd-210467 · Cited by 8
(2006) · PubMed
Metadata
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1996-03
- Volume
- 11
- Issue
- 2
- Pages
- 136-142
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2606710341
- Cited by
- 2,079
- References
- 2
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
